O. Bălăcescu, Simona Vișan, Oana Baldasici, L. Balacescu, C. Vlad, P. Achimas-Cadariu
{"title":"MiRNA-Based Therapeutics in Oncology, Realities, and Challenges","authors":"O. Bălăcescu, Simona Vișan, Oana Baldasici, L. Balacescu, C. Vlad, P. Achimas-Cadariu","doi":"10.5772/INTECHOPEN.81847","DOIUrl":null,"url":null,"abstract":"As master modulators of the human genome, miRNAs are involved in all cancer hallmarks, disrupting the normal function of their targets. By gaining or losing the function, miRNAs lead to the validation of tumor phenotype, its progression, and metastasis as well as to drug resistance. Increasing the evidence suggests that the modulation of miRNAs in cancer cells, by suppressing the oncogenic miRNAs (oncomiRs) and substituting the deficient tumor suppressive miRNAs (TS-miRNAs), could become a reliable tool for improving the cancer therapy. In this chapter, we will present an up-to-date overview of the role of miRNA-based therapeutics in oncology, highlighting their role in cancer management, how these therapies can be used, and which would be the future challenges related to miRNA-based therapies. invasion and metastases (e.g. miR-10b, miR-31, miR-200 family, miR-21, miR-15b), reprogramming energy metabolism","PeriodicalId":401328,"journal":{"name":"Antisense Therapy","volume":"47 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2018-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"17","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antisense Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5772/INTECHOPEN.81847","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 17
Abstract
As master modulators of the human genome, miRNAs are involved in all cancer hallmarks, disrupting the normal function of their targets. By gaining or losing the function, miRNAs lead to the validation of tumor phenotype, its progression, and metastasis as well as to drug resistance. Increasing the evidence suggests that the modulation of miRNAs in cancer cells, by suppressing the oncogenic miRNAs (oncomiRs) and substituting the deficient tumor suppressive miRNAs (TS-miRNAs), could become a reliable tool for improving the cancer therapy. In this chapter, we will present an up-to-date overview of the role of miRNA-based therapeutics in oncology, highlighting their role in cancer management, how these therapies can be used, and which would be the future challenges related to miRNA-based therapies. invasion and metastases (e.g. miR-10b, miR-31, miR-200 family, miR-21, miR-15b), reprogramming energy metabolism
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
